< Back to previous page
Researcher
Dirk Daelemans
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Department of Microbiology, Immunology and Transplantation (Department)
Member
From1 Oct 2013 → 31 Oct 2013 - Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Oct 2000 → Today
Projects
21 - 29 of 29
- iKap: Targeting nucleocytoplasmic transport for novel anti-cancer therapy.From1 Oct 2015 → 30 Nov 2019Funding: SBO (Strategic basic research)
- Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancerFrom1 Jul 2015 → 31 Dec 2022Funding: Foreign Nonprofit organisations and equivalents
- Nuclear-cytoplasmic transport as novel therapeutic target.From1 Oct 2014 → 30 Sep 2018Funding: IOF - Industrial Research Fund
- An automated platform for multiparameter data collection on live pathogens of higher or unknown biosafety risk.From26 Jun 2014 → 31 Dec 2018Funding: Hercules - Large scale research infrastructure
- IDENTIFICATION AND VALIDATION OF DRUG-TARGET INTERACTIONS USING CRISPR/CAS-MEDIATED GENOME EDITINGFrom1 Oct 2013 → 27 Apr 2018Funding: BOF - Doctoral projects
- Visualization of the transport of single-molecule Rev-dependent HIV-1 mRNA species in living cells.From1 Jan 2012 → 31 Dec 2014Funding: FWO research grant KAN
- The Rev-dependent nucleocytoplasmatic mRNA transport as a new target for anti-HIV therapyFrom1 Jan 2011 → 2 Jun 2015Funding: IWT personal funding - strategic basic research grants
- Characterization of an HIV Rev multimerization inhibiting nanobody.From1 Jan 2010 → 31 Dec 2012Funding: FWO research grant KAN
- The influenza virus endonuclease: an innovative target for antiviral therapy.From1 Aug 2009 → 24 Apr 2015Funding: IWT personal funding - strategic basic research grants
Publications
1 - 10 of 155
- Synthesis and Biological Evaluation of Novel Amino and Amido Substituted Pentacyclic Benzimidazole Derivatives as Antiproliferative Agents(2024)
Authors: Dirk Daelemans
- New sugar-incorporated N-heterocyclic carbene precursors and their Ag(I) and Pd(II) complexes: Synthesis, characterization, and cytotoxicity studies(2024)
Authors: Dirk Daelemans, Wim Dehaen, Luc Van Meervelt
- Development of a novel class of Exportin 1 (XPO1/CRM1) inhibitors for anti-cancer therapy(2023)
Authors: Felien Reniers, Wim Dehaen, Dirk Daelemans
- 4-Octyl itaconate reduces influenza A replication by targeting the nuclear export protein CRM1(2023)
Authors: Dirk Daelemans
- Synthesis and Antiproliferative Activity of 2,6-Disubstituted Imidazo[4,5-b]pyridines Prepared by Suzuki Cross Coupling(2023)
Authors: Dirk Daelemans
- Polyketide Synthase-Mediated O-Methyloxime Formation in the Biosynthesis of the Oximidine Anticancer Agents(2023)
Authors: Eveline Vriens, Dries De Ruysscher, Sofie Dekimpe, Gert Steurs, Ahmed Shemy, Dirk Daelemans, Wim De Borggraeve, Eveline Lescrinier, Joleen Masschelein
- TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry(2023)
Authors: Jim Baggen, Maarten Jacquemyn, Els Vanstreels, Hendrik Jan Thibaut, Piet Maes, Dirk Daelemans
Pages: 3427 - + - Novel hydroxy- and amidino-substituted benzimidazoles and benzothiazoles as antibacterial and antiproliferative agents(2023)
Authors: Dirk Daelemans
Pages: 1251 - 1272 - Biological evaluation of novel amidino substituted coumarin-benzazole hybrids as promising therapeutic agents(2023)
Authors: Dirk Daelemans
Pages: 957 - 968 - Novel Biologically Active N-Substituted Benzimidazole Derived Schiff Bases: Design, Synthesis, and Biological Evaluation(2023)
Authors: Dirk Daelemans